山东大学耳鼻喉眼学报 ›› 2023, Vol. 37 ›› Issue (1): 41-46.doi: 10.6040/j.issn.1673-3770.0.2021.502

• 论著 • 上一篇    

miR-181b-5P和EPB41L3蛋白在喉癌中的表达及临床意义

黄恒丰1,2,马鲲鹏2,杨迪1,2,张丽君2,张盛林3   

  1. 1.潍坊医学院 临床医学院, 山东 潍坊 261031;
    2.潍坊医学院附属医院 耳鼻咽喉头颈外科, 山东 潍坊 261031;
    3.潍坊医学院 网络信息中心, 山东 潍坊 261042
  • 发布日期:2023-02-06
  • 通讯作者: 马鲲鹏. E-mail:maxiaofei918@126.com
  • 基金资助:
    潍坊市科学技术发展计划项目(2020GX023)

Expression and clinical significance of miR-181b-5P and EPB41L3 protein in laryngeal squamous cell carcinoma

HUANG Hengfeng1,2, MA Kunpeng2, YANG Di1,2, ZHANG Lijun2, ZHANG Shenglin3   

  1. 1. School of Clinical Medicine, Weifang Medical University, Weifang 261031, Shandong, China;
    2. Department of Otorhinolaryngology & Head and Neck Surgery, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, China;
    3. Department of Network Information Center, Weifang Medical University, Weifang 261042, Shandong, China
  • Published:2023-02-06

PDF (PC)

96

摘要： 目的 miR-181b-5P和红细胞膜蛋白配体4.1样3(EPB41L3)目前在喉癌中表达关系及作用机制尚不明确。论文主要通过研究miR-181b-5P、EPB41L3蛋白在喉癌组织及癌旁正常组织中表达水平并进行相关性分析,探讨miR-181b-5P靶向调控EPB41L3对喉癌组织增殖、侵袭及转移的影响。 方法 通过生物信息学数据库预测miR-181b-5P在喉癌中的表达情况,采用实时荧光定量PCR技术测定喉癌及癌旁正常组织中miR-181b-5P的表达量。预测miR-181b-5p的靶基因并进行生物信息学分析,EPB41L3蛋白的相对表达由免疫组化SP法测定。 结果 喉癌组织中miR-181b-5P的表达明显较癌旁正常组织高(P<0.001),且在有无淋巴结转移间有显著差异(P=0.027 3)。EPB41L3蛋白在喉癌组织的表达明显较癌旁正常组织低(P<0.001)。EPB41L3蛋白在喉癌中的阳性表达率于不同病理分化程度、临床分期及有无淋巴结转移中差异具有统计学意义(P<0.05)。miR-181b-5p及EPB41L3蛋白在喉癌组织中的表达呈负相关(r=-0.420 8,P=0.002 3)。 结论 miR-181b-5P可能通过负性调控EPB41L3的表达,影响喉癌组织的增殖、侵袭、转移,研究可为喉癌的临床靶向治疗提供新的思路。

关键词: 喉癌, miR-181b-5P, EPB41L3, 免疫组织化学, 实时荧光定量PCR

Abstract: Objective Currently, the expression relationship and mechanism of miR-181b-5P and Erythrocyte Membrane Protein Band 4.1-like 3(EPB41L3)in laryngeal cancer are still unclear. This paper mainly studied the expression levels of miR-181b-5P and EPB41L3 protein in laryngeal squamous cell carcinoma tissues and adjacent normal tissues, and than conducted correlation analysis. To explore the effects of miR-181b-5P targeted regulation of EPB41L3 on the proliferation, invasion and metastasis of laryngeal neoplasms. Methods Using bioinformatics databases predicted the expression of miR-181b-5P in laryngeal cancer, and quantitative real-time PCR was used to determine the expression of miR-181b-5P in laryngeal squamous cell carcinoma and adjacent normal tissues. The target genes of miR-181b-5P were predicted and analyzed by bioinformatics. The relative expression of EPB41L3 protein was detected by immunohistochemistry. Results The expression of miR-181b-5P in laryngeal carcinoma tissues was significantly higher than that in adjacent normal tissues(P<0.001), and there was significant difference in laryngeal carcinoma tissues with or without lymph node metastasis(P=0.027 3).The expression of EPB41L3 protein in laryngeal carcinoma tissues was significantly lower than that in adjacent normal tissues(P<0.001).The positive expression rate of EPB41L3 protein was obviously different in different pathological differentiation degrees, clinical stages and lymph node metastasis(P<0.05). The expressions of miR-181b-5p and EPB41L3 protein in laryngeal carcinoma tissues were negatively correlated(r=-0.420 8, P=0.002 3). Conclusion miR-181b-5p may negatively regulate the expression of EPB41L3 and than affect the proliferation, invasion and metastasis of laryngeal cancer. This study maybe provide new ideas for clinical targeted therapy of laryngeal cancer.

Key words: Laryngeal cancer, miR-181b-5P, EPB41L3, Immunohistochemistry, Quantitative real-time PCR

中图分类号: 

  • R767.1
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi:10.3322/caac.21442
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi:10.3322/caac.21492
[3] 周恩, 肖禹, 肖旭平. 等离子射频消融技术在早期声门型喉癌治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 9-15. doi:10.6040/j.issn.1673-3770.1.2020.101 ZHOU En, XIAO Yu, XIAO Xuping. Application progress of radiofrequency ablation technology in the treatment of early glottic carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(2): 9-15. doi:10.6040/j.issn.1673-3770.1.2020.101
[4] 庞振文, 黄愉峰, 杨爱芳, 等. 喉癌患者术前中性粒细胞/淋巴细胞比值与淋巴结转移的相关性研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 58-62. doi:10.6040/j.issn.1673-3770.0.2019.546 PANG Zhenwen, HUANG Yufeng, YANG Aifang, et al. Correlation between Preoperative neutrophil/lymphocyte ratio and lymph node metastasis in patients with laryngeal cancer[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(6): 58-62. doi:10.6040/j.issn.1673-3770.0.2019.546
[5] Bai H, Wu SH. miR-451: a novel biomarker and potential therapeutic target for cancer[J]. Onco Targets Ther, 2019, 12: 11069-11082. doi:10.2147/OTT.S230963
[6] Peka K, Klicka K, Grzywa TM, et al. miR-96-5p, miR-134-5p, miR-181b-5p and miR-200b-3p heterogenous expression in sites of prostate cancer versus benign prostate hyperplasia-archival samples study[J]. Histochem Cell Biol, 2021, 155(3): 423-433. doi:10.1007/s00418-020-01941-2
[7] Rupaimoole R, Slack FJ. microRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222. doi:10.1038/nrd.2016.246
[8] Peng Y, Croce CM. The role of microRNAs in human cancer[J]. Signal Transduct Target Ther, 2016, 1: 15004. doi:10.1038/sigtrans.2015.4
[9] Perge P, Decmann á, Pezzani R, et al. Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors[J]. Endocrine, 2018, 59(2): 280-287. doi:10.1007/s12020-017-1506-z
[10] Indrieri A, Carrella S, Carotenuto P, et al. The pervasive role of the miR-181 family in development, neurodegeneration, and cancer[J]. Int J Mol Sci, 2020, 21(6): E2092. doi:10.3390/ijms21062092
[11] Hu RH, Zhang ZT, Wei HX, et al. LncRNA ST7-AS1, by regulating miR-181b-5p/KPNA4 axis, promotes the malignancy of lung adenocarcinoma[J]. Cancer Cell Int, 2020, 20(1): 568. doi:10.1186/s12935-020-01652-7
[12] Chen S, Liu Y, Wang YY, et al. LncRNA CCAT1 promotes colorectal cancer tumorigenesis via A miR-181b-5p/TUSC3 axis[J]. Onco Targets Ther, 2019, 12: 9215-9225. doi:10.2147/OTT.S216718
[13] Tomihara H, Yamada D, Eguchi H, et al. microRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy[J]. Cancer Sci, 2017, 108(3): 398-407. doi:10.1111/cas.13159
[14] Son HJ, Choi EJ, Yoo NJ, et al. Mutation and expression of a candidate tumor suppressor gene EPB41L3 in gastric and colorectal cancers[J]. Pathol Oncol Res, 2020, 26(3): 2003-2005. doi:10.1007/s12253-019-00787-x
[15] Zhu LY, Yang NH, Chen J, et al. LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p[J]. Oncotarget, 2017, 8(38): 63724-63737. doi:10.18632/oncotarget.18892
[16] Qiu XL, Guan XY, Liu WX, et al. DAL-1 attenuates epithelial to mesenchymal transition and metastasis by suppressing HSPA5 expression in non-small cell lung cancer[J]. Oncol Rep, 2017, 38(5): 3103-3113. doi:10.3892/or.2017.6000
[17] Wang H, Xu M, Cui XB, et al. Aberrant expression of the candidate tumor suppressor gene DAL-1 due to hypermethylation in gastric cancer[J]. Sci Rep, 2016, 6: 21755. doi:10.1038/srep21755
[18] Wang Z, Zhang J, Ye M, et al. Tumor suppressor role of protein 4.1B/DAL-1[J]. Cell Mol Life Sci, 2014, 71(24): 4815-4830. doi:10.1007/s00018-014-1707-z
[19] Zeng R, Liu Y, Jiang ZJ, et al. EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma[J]. Int J Oncol, 2018, 52(5): 1443-1454. doi:10.3892/ijo.2018.4316
[20] Guo Z, Zhang XF, Zhu HB, et al. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2[J]. Oncol Rep, 2021, 45(2): 523-534. doi:10.3892/or.2020.7890
[21] Steuer CE, El-Deiry M, Parks JR, et al. An update on larynx cancer[J]. CA Cancer J Clin, 2017, 67(1): 31-50. doi:10.3322/caac.21386
[22] Guo F, Tang CC, Li YW, et al. The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-κB signalling pathway[J]. J Cell Mol Med, 2018, 22(10): 5062-5075. doi:10.1111/jcmm.13790
[23] Wang L, Wang YX, Chen LP, et al. Upregulation of microRNA-181b inhibits CCL18-induced breast cancer cell metastasis and invasion via the NF-κB signaling pathway[J]. Oncol Lett, 2016, 12(6): 4411-4418. doi:10.3892/ol.2016.5230
[24] Zhou Y, Zheng X, Chen LJ, et al. microRNA-181b suppresses the metastasis of lung cancer cells by targeting sex determining region Y-related high mobility group-box 6(Sox6)[J]. Pathol Res Pract, 2019, 215(2): 335-342. doi:10.1016/j.prp.2018.12.009
[25] Yang XF, Sun Y, Zhang Y, et al. Downregulation of miR181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF-κB signaling pathway[J]. Int J Mol Med, 2020, 46(5): 1755-1764. doi:10.3892/ijmm.2020.4720
[26] Jiang ZL, Zhang FX, Zhan HL, et al. miR-181b-5p promotes the progression of cholangiocarcinoma by targeting PARK2 via PTEN/PI3K/AKT signaling pathway[J]. Biochem Genet, 2022, 60(1): 223-240. doi:10.1007/s10528-021-10084-5
[27] Yeon M, Kim Y, Pathak D, et al. The CAGE-miR-181b-5p-S1PR1 axis regulates anticancer drug resistance and autophagy in gastric cancer cells[J]. Front Cell Dev Biol, 2021, 9: 666387. doi:10.3389/fcell.2021.666387
[28] Yuan X, Piao L, Wang L, et al. Pivotal roles of protein 4.1B/DAL1, a FERMdomain containing protein, in tumor progression(Review)[J]. Int J Oncol, 2019, 55(5): 979-987. doi:10.3892/ijo.2019.4877
[29] Wang CB, Li KY, Men YL, et al. Protein 4.1B suppresses tumor metastasis by regulating epithelial-mesenchymal transition progression in melanoma cells[J]. Int J Med Sci, 2019, 16(4): 529-536. doi:10.7150/ijms.27401
[30] Yuan XF, Piao LH, Wang LH, et al. Erythrocyte membrane protein band 4.1-like 3 inhibits osteosarcoma cell invasion through regulation of Snai1-induced epithelial-to-mesenchymal transition[J]. Aging(Albany NY), 2020, 13(2): 1947-1961. doi:10.18632/aging.202158
[1] 李利杰,田秀芬. CO2激光联合低温等离子治疗早期声门型喉癌40例[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 79-85.
[2] 王媚 李志海. 喉癌干细胞:克服多药耐药性的潜在治疗靶点[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 120-128.
[3] 王晓亭,陈正侬,易红良. 利用RNA-seq探讨谷氨酰胺剥夺对喉癌细胞转录组的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 26-31.
[4] 冯成敏,敬一丹,刘海,王冰. 咽喉部鳞状细胞癌细胞系[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 113-124.
[5] 李艳杰, 贾建,杨萍,万保罗. 肿瘤异常蛋白在喉癌临床诊断中的价值研究[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 70-74.
[6] 陈国平,傅敏仪,叶飞,徐建慧. 早期声门型喉癌钬激光与CO2激光手术对比研究[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 8-11.
[7] 吴允刚,张辉,孙聚兴,刘涛,王彩华,杨欣欣,马林祥,李笑颖,庞太忠,李晓瑜. 环甲膜联合喉室入路切除T1B声门型喉癌临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 30-34.
[8] 薛刚,孙新民,林旭,吴靖芳. KCNK5双孔钾通道蛋白在甲状腺乳头状癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 64-69.
[9] 石玉琦,佘翠平,张庆丰,刘得龙,焦梦思. 早期声门型喉癌低温等离子射频术后喉部感染诊治经验与教训[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 129-134.
[10] 周恩,肖禹,肖旭平. 等离子射频消融技术在早期声门型喉癌治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 9-15.
[11] 肖旭平,周恩,肖禹. 等离子点状激发射频消融技术治疗早期声门型喉癌(Tis-T1b)31例[J]. 山东大学耳鼻喉眼学报, 2021, 35(2): 60-66.
[12] 崔小缓,李丽娜,张延平,蒋兴旺,毕欣欣,冉桃桃,吴莹莹,刘雅莉. 改良负压封闭引流装置在难治性咽瘘治疗中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 49-53.
[13] 庞振文,黄愉峰,杨爱芳,曾先捷. 喉癌患者术前中性粒细胞/淋巴细胞比值与淋巴结转移的相关性研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 58-62.
[14] 谭凤武,邓亚萍,黎可华. 低温等离子射频消融与CO2激光手术治疗早期声门型喉癌疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 63-71.
[15] 徐进敬,胡京华,吴元庆,邓毅,喻唯唯. CO2激光显微手术在喉癌前病变和早期声门型喉癌中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 129-133.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发